Effects of peroxisome proliferator activated receptors-α and -γ agonists on estradiol-induced proliferation and hyperplasia formation in the mouse uterus

A G Gunin, A D Bitter, A B Demakov, E N Vasilieva and N V Suslonova

Department of Obstetrics and Gynecology, Medical School, Chuvash State University, P.O. Box 86, Cheboksary 428034, Russia

(Requests for offprints should be addressed to A G Gunin; Email: drgunin@myrealbox.com)

Abstract

It is suggested that the action of peroxisome proliferator-activated receptors (PPARs) cross-talks with estrogen signaling in the uterus. However, it is not known how PPAR agonists affect estrogen–dependent processes in the uterus, especially proliferation and morphogenetic changes. The effects of agonists of PPAR-α and -γ on proliferative and morphogenetic reactions in the uterus under short- and long-term estrogen treatments were therefore examined. Ovariectomized mice were treated with estradiol dipropionate (4 µg/100 g, s.c., once a week) or vehicle and rosiglitazone (PPAR-γ agonist) or fenofibrate (PPAR-α agonist) or with no additional treatment for 2 days or for 30 days. Treatment with estradiol and PPAR agonists for 2 days did not affect uterine mass. In mice treated with estradiol and rosiglitazone for 2 days, proliferation was enhanced and levels of estrogen receptors-α and β-catenin were decreased in all uterine tissues. Treatment with estradiol and fenofibrate for 2 days had the opposite effects on the parameters tested. In animals treated with estradiol and rosiglitazone for 30 days, uterine mass was increased, abnormal uterine glands and atypical endometrial hyperplasia were found more often and levels of estrogen receptors-α and β-catenin were decreased. In animals treated with estradiol and fenofibrate for 30 days, uterine mass was decreased, most of the uterine glands had a normal structure, no cases of atypical hyperplasia were diagnosed, proliferative activity was declined and the levels of estrogen receptors-α and β-catenin were markedly higher. Treatment with rosiglitazone or fenofibrate did not affect the serum estradiol level in the mice which received estradiol together with PPAR agonists for 30 days. Thus, rosiglitazone exerted the proliferative and morphogenetic effects of estradiol, but fenofibrate had the opposite effect. The actions of rosiglitazone and fenofibrate are associated with changes in the expression of estrogen receptors-α and β-catenin in the uterus.


Introduction

Estrogen hormones induce powerful proliferation and changes in the structure of tissues in the uterus (Martin et al. 1973, Bigsby 2002). The culmination of these estrogen-induced changes in proliferation and morphogenesis is the formation of cancer in the endometrium (Emons et al. 2000, Akhmedkhanov et al. 2001). Endometrial cancer can be easily induced in laboratory rodents by treatment with estrogens (Akhmedkhanov et al. 2001). The incidence of this pathology in women is more often when increased estrogen levels or unopposed treatment with estrogen hormones are present (Deligdisch 2000). In addition, it is now absolutely clear that endometrial cancer is an estrogen–dependent disease. In spite of some progress in our understanding of the interactions between estrogen and the uterus and in estrogen hormone signaling, thousands of cases of endometrial cancer are registered each year in all countries. Thus, new aspects of estrogen action in the uterus or new steps in estrogen signaling must be discovered to achieve more effective prevention and treatment of estrogen-dependent diseases.

Peroxisome proliferator-activated receptors (PPARs) and compounds acting on these receptors have a variety of powerful effects in the organism (Elangbam et al. 2001, Shearer & Hoekstra 2003). There are three types of PPAR, α, β and γ (Shearer & Hoekstra 2003). PPAR-α and PPAR-γ have been documented in the uterus (Houston et al. 2003). It is also interesting that in the past some shared steps, mostly indirect and controversial, between estrogen signaling and PPAR have been found. There are some works documenting interactions between PPAR-γ and estrogen signaling or uterine physiology. It has been shown that activation of PPAR-γ...
inhibits the growth of uterine leiomyoma, which is also an estrogen-dependent disease (Houston et al. 2003). It was supposed that this inhibitory action was mediated by the negative influence of PPAR-γ on estrogen receptor signaling (Houston et al. 2003). It was found that PPAR-γ ligands stimulate secretion of some cytokines (interleukin (IL)-1, IL-6, colony stimulation factor-1 (CSF-1)) by endometrial cells (Wanichkul et al. 2003). There is also an observation showing that PPAR-γ ligands reduce chemokine production in human endometrial stromal cells (Pritts et al. 2002). Some reports indicate that PPAR-γ could mediate the expression of estrogen target genes and could attenuate estrogen receptors and cyclin D1 levels (Keller et al. 1995, Wang & Kilgore 2002, Houston et al. 2003, Qin et al. 2003). It has also been shown that PPAR-γ coactivator-1 potently enhances the activity of estrogen receptor-α (Kressler et al. 2002). Estradiol treatment was demonstrated to inhibit the ligand-stimulated transactivation of PPAR-γ in breast cancer cells (Wang & Kilgore 2002).

There are also only a few data which show interactions between PPAR-α and estrogen-dependent events in the uterus. PPAR-α agonists have been shown to possess uterotrophic action, which is also synergized with the uterotrophic effect of estradiol (Chandra et al. 1982). However, other researchers have documented no effect (Ashby et al. 1997).

Thus, there is some evidence that PPARs can alter the intracellular estrogen signaling pathway. Hence, it can be suggested that PPARs can affect estrogen-dependent processes, such as proliferation and morphogenetic shifts, in the uterus. However, there are no data on this problem. Therefore, the effects of agonists of PPAR-α and -γ on proliferative and morphogenetic reactions in the uterus under short- and long-term estrogen treatment were examined in this work.

### Materials and Methods

#### Animals

All procedures were performed in accordance with the UFAW Handbook on the Care and Management of Laboratory Animals and with the Chuvash State University rules for work with laboratory animals. White non-linear female mice (20·33 ± 0·33 g; mean ± S.E.M.) of 3 months of age were used. Animals were obtained from the Animal Department of Chuvash State University (Cheboksary, Russia) and were housed with free access to water and food. Mice were ovariectomized 2 weeks before the experiments were started. All surgical procedures were performed under anesthesia with ketamine and diazepam (75 mg/kg, 0·12 mg/kg respectively, i.p.; Gedeon-Richter, Budapest, Hungary).

#### Treatment

Ovariectomized mice were divided into several groups according to treatment, as follows and as shown in Table 1.

The first group of mice (n=7) was treated with a single s.c. injection of estradiol dipropionate in olive oil (Minmedprom, Rostov-Don, Russia) at a dose of 4 µg/100 g body mass and allowed to drink tap water with 0·005% (w/v) rosiglitazone (Avandia; GlaxoSmithKline, Brentford, Essex, UK) for 2 days. The second group of mice (n=7) was treated with a single injection of estradiol and fed mouse chow with 0·2% (w/w) fenofibrate (Sigma Chemical Co., St Louis, MO, USA) for 2 days. The third group of animals (n=7) was treated with a single injection of estradiol with no additional treatment for 2 days. The fourth (n=5), fifth (n=5) and sixth (n=5) groups received a single injection of estradiol vehicle and rosiglitazone or fenofibrate, or with no additional treatment respectively.

<table>
<thead>
<tr>
<th>Group no.</th>
<th>Estradiol</th>
<th>Estradiol vehicle</th>
<th>Rosiglitazone (PPAR-γ agonist)</th>
<th>Fenofibrate (PPAR-α agonist)</th>
<th>No. of animals</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td></td>
<td>7</td>
</tr>
<tr>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>7</td>
</tr>
<tr>
<td>3</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td></td>
<td>7</td>
</tr>
<tr>
<td>4</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td></td>
<td>5</td>
</tr>
<tr>
<td>5</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td></td>
<td>5</td>
</tr>
<tr>
<td>6</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td></td>
<td>5</td>
</tr>
<tr>
<td>7</td>
<td>30</td>
<td>30</td>
<td>30</td>
<td>30</td>
<td>14</td>
</tr>
<tr>
<td>8</td>
<td>30</td>
<td>30</td>
<td>30</td>
<td>30</td>
<td>14</td>
</tr>
<tr>
<td>9</td>
<td>30</td>
<td>30</td>
<td>30</td>
<td>30</td>
<td>14</td>
</tr>
<tr>
<td>10</td>
<td>30</td>
<td>30</td>
<td></td>
<td></td>
<td>5</td>
</tr>
<tr>
<td>11</td>
<td>30</td>
<td>30</td>
<td>30</td>
<td>30</td>
<td>5</td>
</tr>
<tr>
<td>12</td>
<td>30</td>
<td>30</td>
<td>30</td>
<td>30</td>
<td>5</td>
</tr>
</tbody>
</table>

Table 1 Experimental design and treatments
for 2 days. The seventh group of mice (n=14) was treated with injections of estradiol once a week and drank water with 0.005% rosiglitazone for 30 days. The eighth group (n=14) received injections of estradiol once a week and was fed mouse chow with 0.2% fenofibrate for 30 days. The ninth group of mice (n=14) was fed mouse chow with 0.2% fenofibrate for 30 days.

The seventh group of mice (n=14) was treated with injections of estradiol once a week and drank water with 0.005% rosiglitazone for 30 days. The eighth group (n=14) received injections of the estradiol vehicle and fenofibrate or fenofibrate, or with no additional treatments respectively for 30 days.

The uteri were removed 48 h after the last estradiol or vehicle injection. All animals were injected i.p. with bromodeoxyuridine (BrdU; 5 mg/100 g body mass; Sigma) dissolved in saline 2 h before the tissues were removed. Organs were removed under deep ether anesthesia. Uteri were weighed and the middle segments of the uterine horns were then placed in modified Bouin’s fixative (Gunin et al. 2000) for 6 h at room temperature, and then dehydrated and embedded in paraffin. Uteri were oriented transversely and cut at 5–7 µm. Estradiol concentration in serum

In groups 7–12, immediately after the uteri were removed, trunk blood was collected, allowed to clot and then centrifuged at 3000 g for 10 min. Serum samples were taken and placed in a refrigerator at −20°C until the analysis was started. Estradiol concentration in serum was determined by the use of the DSL Estradiol EIA Kit (Diagnostic Systems Laboratories Inc., Webster, TX, USA) according to the manufacturer’s protocol. A Bio-Rad reader (Hercules, CA, USA) was used. The minimal estradiol concentration which can be detected with these reagents is 7 pg/ml.

Uterine histology

Histological changes in the uterus were analyzed and diagnosed according to Scully et al. (1994). To estimate the extent of any hyperplastic or neoplastic changes in the endometrium, uterine glands were subdivided into four morphological types: (1) normal glands, (2) cystic glands, (3) glands with daughter glands and (4) a conglomerate of glands, as described by Gunin et al. (2001). The number of each type of glands was calculated in randomly selected sections. No less than three sections from each animal were examined. Results are expressed as the percent of each type of gland. The epithelium of all glands in randomly selected sections was examined and sized as simple, pseudostratified or stratified (multilayered) epithelium. The percent of glands with each type of epithelium was calculated.

The number of mitotic and BrdU-labeled cells

Proliferative processes were assessed from the number of mitotic and BrdU-labeled cells. Mitoses were counted in sections stained with iron hematoxylin. BrdU was detected immunohistochemically. Sections were hydrated and put in 4 M HCl for 20 min. Slides were then placed in 0.05% (w/v) trypsin in Tris–buffered saline (TBS), pH 7.2–7.6 for 20 min. The sections were rinsed (3 × 10 min) in TBS. Non-specific binding was blocked with the avidin and biotin blocking solutions (Vector Laboratories, Burlingame, CA, USA) for 30 min each. Tissues were then incubated overnight with anti-BrdU mouse monoclonal antibody conjugated with biotin (Clat Laboratories, Burlingame, CA, USA) diluted 1:50 in TBS with 1% (v/v) blocking solution (Immunotech, Marseille, France) and 0.1% (v/v) Triton X-100. After being rinsed in TBS (3 × 20 min), sections were incubated for 1 h with streptavidin conjugated with alkaline phosphatase (Clat Laboratories) diluted 1:50 in TBS with 0.1% (v/v) Triton X-100. The sections were then rinsed in TBS (3 × 20 min). Alkaline phosphatase activity was revealed through the use of naphthol AS-BI-phosphate (Sigma) and new fuchsin (Sigma) as chromogens. Control sections were stained in a similar manner, except that the primary antibody was replaced with normal mouse serum. The numbers of mitotic and BrdU-labeled cells in luminal epithelium, glandular epithelium, stromal cells and myometrial cells were found as described by Gunin et al. (2001). No less than 3000 epithelial and 10 000 stromal or myometral cells were assessed per mouse. All results are expressed as the percent of mitotic or labeled cells.

Estrogen receptors-α and β-catenin

Estrogen receptors-α and β-catenin were detected using routine indirect immunohistochemical staining. Rabbit anti-estrogen receptor-α polyclonal antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) diluted 1:50 and rabbit anti-β-catenin antiserum (Sigma Chemical Co.) diluted 1:50 were used as primary antibody. For the detection of estrogen receptors, goat anti-rabbit immunoglobulin G antibody conjugated with alkaline phosphatase (Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA) was used as secondary antibody, and alkaline phosphatase activity was then revealed using naphthol AS-BI-phosphate and new fuchsin as chromogens. For β-catenin, goat anti-rabbit immunoglobulin G antibody conjugated with peroxidase (Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA) was utilized as secondary antibody. Peroxidase activity was then developed by the use of the hydrogen peroxide and diaminobenzidine (Sigma Chemical Co.) technique and slides were also preincubated in 0.1% hydrogen peroxide in distilled water for 10 min to block endogenous peroxidase activity. Control sections were stained in a similar manner, except that the primary antibody was replaced with normal rabbit serum. To avoid possible differences in the intensity of staining, sections from all mice were processed simultaneously for each antigen, so that all sections were

www.endocrinology.org
incubated in exactly the same TBS, the same mixtures of primary and secondary antibodies, the same mixture for development of enzyme activity, for the same times, at the same temperature. Intensity of immunostaining was quantified by photometric measurement of optical density (D) for positive stained components of a tissue (Gunin et al. 2002). Photometry was performed using a light microscope and FMEL-1A microspectrophotometer (LOMO, St Petersburg, Russia) by measuring the intensity of light passing through equivalent areas occupied by positive stained structures (F) and by structures with no staining (F₀). Optical density (light absorption) was calculated from the formula: D=lg(F₀/F). Positive staining for estrogen receptors was detected in the nuclei of all uterine tissues (luminal epithelium, glandular epithelium, stromal cells, myometrial cells). Therefore, the intensity of light passing through the nuclei (F; positive staining) and through the cytoplasm (F₀; negative staining) was measured in the case of estrogen receptors. β-Catenin was detected in luminal and glandular epithelia. Therefore, the intensity of light passing through the cytoplasm of these epithelial cells (F; positive staining) and through the endometrial stromal cells (F₀; negative staining) was measured in the case of β-catenin. The level of expression was considered to be the value of the optical density (Gunin et al. 2002, 2004). At least 100 nuclei were analyzed for each structure in each mouse.

**Statistics**

Arithmetic means and standards errors were calculated for each data group. The significance of differences was determined by non-parametric Mann–Whitney U test (uterine mass, estradiol serum level, proliferation, estrogen receptors, β-catenin) and by use of the chi-square test (gland types, epithelium types, pathology). *P*<0.05 was considered to be significant.

**Results**

**Estradiol levels in serum**

Estradiol concentrations in serum were measured in the groups treated for 30 days. As expected, estradiol was not detected in any of the groups of ovariectomized mice which were treated with olive oil instead of estradiol (groups 11–13). In control mice treated with estradiol with no additional treatments for 30 days (group 9), estradiol concentration in serum was 136 ± 12 pg/ml. In animals receiving estradiol and rosiglitazone for 30 days (group 7), the estradiol concentration was 135 ± 23 pg/ml, and in mice treated with estradiol and fenofibrate (group 8), the estradiol level was 138 ± 17 pg/ml. There were no statistically significant differences from the data of control mice treated with estradiol only.

**Uterine mass**

The uterine mass of ovariectomized mice receiving olive oil instead of estradiol with no additional treatment for 2 or 30 days (groups 3 and 12) was 123·7 ± 21·5 or 120·1 ± 24·9 pg/100 g body mass (n=5) respectively. The addition of olive oil treatment to fenofibrate or rosiglitazone for 3 or 30 days had no effect on uterine mass.

In mice receiving estradiol and rosiglitazone for 2 days (group 1), uterine mass was elevated, but this elevation was not significant (Fig. 1). The uterine mass of mice receiving estradiol and fenofibrate for 2 days (group 2) did not differ much from control.

Treatment with estradiol and rosiglitazone for 30 days (group 7) resulted in a 20% increase in uterine mass, whereas treatment with estradiol and fenofibrate (group 8) produced a 21% decrease in this parameter (Fig. 1). Changes in 30-day treatment groups were statistically significant (*P*<0.05).

**Uterine histology**

All uteri of ovariectomized mice which were not treated with estradiol and received rosiglitazone or fenofibrate, or with no additional treatment for 2 or 30 days (groups 4–6 and 10–12) were diagnosed as showing atrophic endometrium. All endometrial glands in all these uteri had a narrow lumen and an round, oval or elongated shape (a microscopical reflection of simple tubular glands),
cells (b-iii), a decrease in levels of estrogen receptors-α (c-ii) and β-catenin (d-ii) in the uterus of mice treated with estradiol and rosiglitazone for 2 days (ii), as compared with controls (b-i, c-i, d-i). On the contrary, 2 days of treatment with estradiol and fenofibrate produces a decrease in the number of BrdU-labeled cells (b-iii), elevated levels of estrogen receptors-α (c-iii) and β-catenin (d-iii) in the uterus, as compared with controls (b-i, c-i, d-i). le, luminal epithelium; g, endometrial glands; s, stromal cells. Scale bar 100 μm (a, b, c) and 200 μm (d).

Figure 2 Photomicrographs demonstrating uterine histology (a) and immunohistochemical staining for BrdU (b), estrogen receptors-α (c) and β-catenin (d) in the uteri of mice treated with estradiol alone (i) or with rosiglitazone (ii) or fenofibrate (iii) for 2 days. No changes in general uterine histology are seen among the groups. There is a marked increase in the number of BrdU-labeled cells (b-ii), a decrease in levels of estrogen receptors-α (c-ii) and β-catenin (d-ii) in the uterus of mice treated with estradiol and rosiglitazone for 2 days (ii), as compared with controls (b-i, c-i, d-i). In control mice receiving estradiol for 30 days (group 9), glands with daughter glands, glands forming conglomerates and glands with atypical stratified columnar epithelium were observed more often (Figs 3 and 4). The incidence of atypical endometrial hyperplasia was found in 53% of cases, and there was no case of normal proliferative endometrium (Figs 3 and 4).

In the uteri of mice treated with estradiol and fenofibrate for 30 days (group 8), most of the glands had a normal shape and there were no gland forming conglomerates. Also, most glands were lined with simple columnar or cuboidal epithelium. In these uteri, no case of atypical endometrial hyperplasia was diagnosed (Figs 3 and 4).

Proliferation

Proliferation in the uterus was estimated by two criteria, the numbers of mitotic and BrdU-labeled cells.

Treatment with estradiol and rosiglitazone for 2 days (group 1) produced an increase in the numbers of mitotic and BrdU-labeled cells in luminal epithelium, the epithelium of endometrial glands and in stromal and myometrial cells of the uterus (Fig. 5). In mice treated with estradiol and fenofibrate for 2 days (group 2), there was a little decrease in all proliferative parameters in all uterine tissues (Fig. 5).

Treatment with estradiol and rosiglitazone for 30 days (group 7) had no significant effect on both proliferative parameters in all uterine tissues (Fig. 5). Treatment with estradiol and fenofibrate for 30 days (group 8) produced a decrease in the number of mitotic and BrdU-labeled cells in all structures, but this decrease was more expressed, especially in epithelia, than that observed in the 2-day treatment protocol (Fig. 5).

Mice which received the estradiol vehicle (olive oil) and rosiglitazone or fenofibrate or with no additional treatment for 30 days (groups 10–12) had no changes in proliferative parameters in all uterine tissues (Fig. 5). Mitotic and BrdU-labelling indices in all uterine tissues of mice receiving olive oil and rosiglitazone or fenofibrate or with no additional treatment for 2 days (groups 4–6) were not different from those of the 30-day olive oil-treated groups and did not differ among each other.

Estrogen receptors-α

Immunohistochemically, estrogen receptors-α were found in luminal and glandular epithelia, in the stromal and myometrial cells of the uterus. Treatment with estradiol and rosiglitazone either for 2 or 30 days (groups 1 and 7) reduced the level of estrogen receptors-α in all uterine compartments, as compared with that in control animals (groups 3 and 9) treated with estradiol (Figs 2, 3 and 6). However, this decrease was not statistically significant in the 2-day treatment group.
In groups treated with estradiol and fenofibrate either for 2 or 30 days (groups 2 and 8), the level of estrogen receptors-α in all uterine structures was significantly higher than that in the appropriate controls (groups 3 and 9) (Figs 2, 3 and 6).

Mice which received the estradiol vehicle (olive oil) and rosiglitazone or fenofibrate or with no additional treatment for 30 days (groups 10–12) had no changes in estrogen receptor expression (Fig. 6). The data on expression of estrogen receptors-α in animals treated with olive oil along with rosiglitazone or fenofibrate for 2 days (groups 4–6) were not different from those of the 30-day olive oil-treated groups and did not differ among each other.

**β-Catenin**

β-Catenin was detected by immunohistochemistry in luminal and glandular epithelia of the uteri of mice in all treatment groups. Treatment with estradiol and rosiglitazone for 2 days (group 1) led to a small decrease in the level of β-catenin in both epithelia, but the same treatment for 30 days (group 7) led to significant decrease in the level of β-catenin in both luminal and glandular epithelia (Figs 2, 3 and 7).

In a group treated with estradiol and fenofibrate for 2 days (group 2), the level of β-catenin was slightly elevated, but the same treatment for 30 days (group 8) produced a significant increase in β-catenin content in luminal and glandular uterine epithelia (Figs 2, 3 and 7).

The data of mice treated with the estradiol vehicle and rosiglitazone or fenofibrate or with no additional treatment for a month (groups 10–12) are shown in Fig. 7c. There were no differences in β-catenin level among these groups. The data on β-catenin level in animals treated with olive oil along with rosiglitazone or fenofibrate or with no additional treatment for 2 days (groups 4–6) were not different from those of the 30-day
their concentration in blood can be a lipid nature. Therefore, metabolism of these hormones and degradation in peroxisomes. Estrogen hormones have a lipid action. There are controversial data concerning the effects of PPAR agonists on estrogen concentration in blood. One source shows that PPAR ligands, especially PPAR-\(\gamma\), decrease estrogen levels in blood (Corton et al. 1997, Xu et al. 2001b). Other data demonstrate activation in estrogen synthesis under PPAR agonists (Liu et al. 1996). There are also studies indicating that the estrogen level remains unaffected with the use of PPAR drugs (Inglis et al. 2001). In our experiments, we used treatment with estradiol together with PPAR-\(\alpha\) or PPAR-\(\gamma\) ligands. Hence, estradiol levels in blood may be changed by PPAR agonists and our results could be due to this effect. To check this situation, the estradiol concentration in blood was determined in groups with 30-day estradiol treatments. The results clearly showed that the estradiol concentration in mice receiving estradiol alone, it can therefore be concluded that our results on the effects of PPAR drugs on estrogen-induced changes in the uterus do not depend on changes in the estradiol level in blood, but are due to other factors which will be analysed below.

In the present research, a group of parameters was used to estimate the action of estradiol in the uterus. Uterine mass is a well-known parameter that depends on estrogen (Eimons et al. 2000, Bigsby 2002). Proliferation, which was determined by the numbers of mitotic and BrdU-labeled cells, also depends on estrogen action (Martin et al. 1973, Gunin et al. 2002). In addition, morphogenetic changes, such as shape of glands, type of glandular epithelium and pathology findings, appear in the uterus under long-term estrogen action (Martin et al. 1973, Gunin et al. 2002).

The results mainly showed that rosiglitazone led to an increase in uterine mass, proliferation and in more expressed morphogenetic alterations than in control mice. In the 30-day treated groups, rosiglitazone had almost no effect on proliferation, but this treatment resulted in an increased incidence of atypical hyperplasia. It is known that proliferation and control of cell shape, differentiation, adhesion and apoptosis are regulated by different mechanisms and depend on the work of different genes (Ing & Ott 1999, Bigsby 2002, Klotz et al. 2002, Simmen et al. 2002). It is possible that rosiglitazone does not affect the genetic machinery which is responsible for proliferation, but affects the pathways regulating the differentiation process that leads to precancerous hyperplasia formation. There are data documenting enhanced tumor formation in the colon under the action of the PPAR-\(\gamma\) agonist (Lefebvre et al. 1998, Michalik et al. 2004). Thus, our data demonstrated that rosiglitazone enhances mainly morphogenetic and, to a lesser degree, proliferative estrogen action on the uterus. Other data have indicated that PPAR-\(\gamma\) agonists affect one estrogen-inductable gene, but others do not (Keller et al. 1995, Houston et al. 2003).

On the contrary, experiments with fenofibrate have shown that uterine mass, proliferation and morphogenetic shifts were less expressed than in control animals. There was no case of atypical endometrial hyperplasia in the estradiol- and fenofibrate-treated groups. Hence, the effect of fenofibrate can be regarded as anti-estrogenic with regard to the proliferation and morphogenesis.

There has been one paper showing that the PPAR-\(\alpha\) agonist clofibrate had no effect on the uterus (Xu et al. 2001a). Our data have demonstrated the opposite situation. The nature of these contradictions is due to differences in experimental designs and PPAR-\(\alpha\) agonists applied in these experiments. In work performed in the laboratory of Dr A H Conney, clofibrate was used as a PPAR-\(\alpha\) agonist, estradiol treatment was prolonged for 10 days and only uterine mass was measured with no histological examination (Xu et al. 2001a). We used fenofibrate as the PPAR-\(\alpha\) agonist, because it has been shown that this compound is less toxic (Guay 2002). In the present work, fenofibrate was used for 30 days in comparison with those in mice treated with estradiol together with rosiglitazone or fenofibrate for 30 days in comparison with those in mice treated with estradiol alone. PE, proliferative endometrium; SH, simple hyperplasia; CoH, complex hyperplasia; AH, atypical hyperplasia; D, glands forming conglomerate; 1, simple columnar epithelium; 2, pseudostratified columnar epithelium; 3, stratified columnar epithelium. Values are means ± S.E.M. P values (chi-square test); NS, not significant.

Figure 4 Types of endometrial glands, types of glandular epithelium and pathology diagnosis in uteri of ovariectomized mice treated with estradiol together with rosiglitazone or fenofibrate for 30 days in comparison with those in mice treated with estradiol alone. PE, proliferative endometrium; SH, simple hyperplasia; CoH, complex hyperplasia; AH, atypical hyperplasia; D, glands forming conglomerate; 1, simple columnar epithelium; 2, pseudostratified columnar epithelium; 3, stratified columnar epithelium. Values are means ± S.E.M. P values (chi-square test); NS, not significant.

Discussion

An effect of PPAR agonists is the activation of lipid degradation in peroxisomes. Estrogen hormones have a lipid nature. Therefore, metabolism of these hormones and their concentration in blood can be affected by PPAR agonists. There are controversial data concerning the effects of PPAR agonists on estrogen concentration in blood. One source shows that PPAR ligands, especially PPAR-\(\alpha\), decrease estrogen levels in blood (Corton et al. 1997, Xu et al. 2001b). Other data demonstrate activation in estrogen synthesis under PPAR agonists (Liu et al. 1996). There are also studies indicating that the estrogen level remains unaffected with the use of PPAR drugs (Inglis et al. 2001). In our experiments, we used treatment with estradiol together with PPAR-\(\alpha\) or PPAR-\(\gamma\) ligands. Hence, estradiol levels in blood may be changed by PPAR agonists and our results could be due to this effect. To check this situation, the estradiol concentration in blood was determined in groups with 30-day estradiol treatments. The results clearly showed that the estradiol concentration in mice receiving estradiol with rosiglitazone or fenofibrate did not differ from that of control mice receiving estradiol alone. It can therefore be concluded that our results on the effects of PPAR drugs on estrogen-induced changes in the uterus do not depend on changes in the estradiol level in blood, but are due to other factors which will be analysed below.

In the present research, a group of parameters was used to estimate the action of estradiol in the uterus. Uterine mass is a well-known parameter that depends on estrogen (Eimons et al. 2000, Bigsby 2002). Proliferation, which was determined by the numbers of mitotic and BrdU-labeled cells, also depends on estrogen action (Martin et al. 1973, Gunin et al. 2002). In addition, morphogenetic changes, such as shape of glands, type of glandular epithelium and pathology findings, appear in the uterus under long-term estrogen action (Martin et al. 1973, Gunin et al. 2002).

The results mainly showed that rosiglitazone led to an increase in uterine mass, proliferation and in more expressed morphogenetic alterations than in control mice. In the 30-day treated groups, rosiglitazone had almost no effect on proliferation, but this treatment resulted in an increased incidence of atypical hyperplasia. It is known that proliferation and control of cell shape, differentiation, adhesion and apoptosis are regulated by different mechanisms and depend on the work of different genes (Ing & Ott 1999, Bigsby 2002, Klotz et al. 2002, Simmen et al. 2002). It is possible that rosiglitazone does not affect the genetic machinery which is responsible for proliferation, but affects the pathways regulating the differentiation process that leads to precancerous hyperplasia formation. There are data documenting enhanced tumor formation in the colon under the action of the PPAR-\(\gamma\) agonist (Lefebvre et al. 1998, Michalik et al. 2004). Thus, our data demonstrated that rosiglitazone enhances mainly morphogenetic and, to a lesser degree, proliferative estrogen action on the uterus. Other data have indicated that PPAR-\(\gamma\) agonists affect one estrogen-inductable gene, but others do not (Keller et al. 1995, Houston et al. 2003).

On the contrary, experiments with fenofibrate have shown that uterine mass, proliferation and morphogenetic shifts were less expressed than in control animals. There was no case of atypical endometrial hyperplasia in the estradiol- and fenofibrate-treated groups. Hence, the effect of fenofibrate can be regarded as anti-estrogenic with regard to the proliferation and morphogenesis.

There has been one paper showing that the PPAR-\(\alpha\) agonist clofibrate had no effect on the uterus (Xu et al. 2001a). Our data have demonstrated the opposite situation. The nature of these contradictions is due to differences in experimental designs and PPAR-\(\alpha\) agonists applied in these experiments. In work performed in the laboratory of Dr A H Conney, clofibrate was used as a PPAR-\(\alpha\) agonist, estradiol treatment was prolonged for 10 days and only uterine mass was measured with no histological examination (Xu et al. 2001a). We used fenofibrate as the PPAR-\(\alpha\) agonist, because it has been shown that this compound is less toxic (Guay 2002). In the present work, fenofibrate was used for 30 days in comparison with those in mice treated with estradiol together with rosiglitazone or fenofibrate for 30 days in comparison with those in mice treated with estradiol alone. PE, proliferative endometrium; SH, simple hyperplasia; CoH, complex hyperplasia; AH, atypical hyperplasia; D, glands forming conglomerate; 1, simple columnar epithelium; 2, pseudostratified columnar epithelium; 3, stratified columnar epithelium. Values are means ± S.E.M. P values (chi-square test); NS, not significant.

Figure 4 Types of endometrial glands, types of glandular epithelium and pathology diagnosis in uteri of ovariectomized mice treated with estradiol together with rosiglitazone or fenofibrate for 30 days in comparison with those in mice treated with estradiol alone. PE, proliferative endometrium; SH, simple hyperplasia; CoH, complex hyperplasia; AH, atypical hyperplasia; D, glands forming conglomerate; 1, simple columnar epithelium; 2, pseudostratified columnar epithelium; 3, stratified columnar epithelium. Values are means ± S.E.M. P values (chi-square test); NS, not significant.
research, minimal changes in uterine weight were also registered in the group receiving estradiol and fenofibrate for 2 days, but a marked decrease in uterine mass occurred with prolongation of the treatment to 30 days. Moreover, histological examination clearly showed the effects of fenofibrate on the estrogen-dependent processes in the uterus.

The effects of PPAR agonists on all parameters tested were found only in estrogen-treated mice and not documented in control animals receiving olive oil instead of estradiol. Hence, this situation allows us to suppose that PPAR agonists affect some steps in the mechanism of estrogen action.

To define some possible mechanisms involved in the action of PPAR agonists on estrogen-induced effects, the expression of estrogen receptors-α and β-catenin in uterine tissues was examined. The results showed that rosiglitazone reduced the level of estrogen receptors-α in all uterine compartments, as compared with the control. In general, the level of receptors in a tissue depends on a balance between their synthesis and degradation (Ing & Ott 1999, Nephew et al. 2000). Rosiglitazone probably attenuates estrogen receptor synthesis or activates the degradation. Fenofibrate probably has the opposite effect on the processes of receptor synthesis and degradation. Other data have also shown that PPAR-γ agonists resulted in...
in a decrease of estrogen receptors-α in the mammary gland cancer cells MCF-7 that was partially due to proteasome-dependent degradation of the receptors (Houston et al. 2003, Qin et al. 2003). However, there are data which show that PPAR-γ agonists can enhance the activity of estrogen receptors-α (Kressler et al. 2002). This latter circumstance may be responsible for an increased incidence of atypical endometrial hyperplasia observed in estrogen- and rosiglitazone-treated animals.

It is interesting to note that in rosiglitazone- and estradiol-treated mice, more intensive estrogen-dependent processes (mass, proliferation, morphogenesis) in the uterus proceed on a lower level of estrogen receptors. In addition, in fenofibrate- and estradiol-treated groups, less intensive estrogen-dependent events are accompanied by increased levels of estrogen receptors. Other data have also shown that more malignant and less-differentiated endometrial tumors have low levels of estrogen receptors (Sivridis et al. 2001). It is possible that a diminished level of estrogen receptors does not allow estrogens to adequately control the processes of managing morphogenesis that leads to atypical hyperplasia formation.
β-Catenin is a component of adhesion junctions and the Wnt pathway (Miller 2002). β-Catenin synthesis and content in the uterus has been shown to be affected by estrogens and to play a role in endometrial carcinogenesis (Fujimoto et al. 1996, Nei et al. 1999). There is a decrease in β-catenin expression in uterine epithelia in mice treated with estradiol and rosiglitazone compared with that of mice treated with estradiol alone. However, both short- and long-term treatments with estradiol and fenofibrate showed an increase in β-catenin content in uterine epithelia. Our results showed that more expressed morphogenetic shifts, which were found in estradiol- and rosiglitazone-treated mice, are accompanied by a decrease in β-catenin. An opposite situation is present in estradiol- and fenofibrate-treated animals. β-Catenin provides intercellular adhesion. It is possible that if the concentration of β-catenin is high, cell–cell connection is more stable which protects from the formation of precancerous changes. In the case of low β-catenin concentration, cell–cell interactions are less solid which provides a situation for the development of cancer. Other data have also shown a decrease in the level of β-catenin in the uterus following estrogen action and cancer formation (Fujimoto et al. 1998, Miyamoto et al. 2000, Gunin et al. 2004).

β-Catenin content in a tissue is also a result of the balance between its synthesis and degradation. It was previously shown that changes in β-catenin expression can be caused by glycogen-synthase kinase-3β, an enzyme which takes part in β-catenin degradation (Gunin et al. 2003). Other data have shown that estrogen hormones can attenuate β-catenin biosynthesis in the uterus (Fujimoto et al. 1996). However, further studies are needed to elucidate the roles of PPAR agonists in the regulation of β-catenin content in the uterus, as well as to define the role of β-catenin in uterine morphogenesis.

Thus, this research has provided evidence that the PPAR-γ agonist rosiglitazone enhances proliferative and morphogenetic estrogen action and supports the development of estrogen-dependent endometrial hyperplasia, and the PPAR-α agonist fenofibrate attenuates the proliferative action of estradiol on the uterus and strongly suppresses the development of precancerous estrogen-dependent endometrial hyperplasia. We hope that this research will lead to a better understanding of the origin and progression of estrogen-dependent cancers of the female reproductive system.

Acknowledgements

This work was supported by grants from the Russian Foundation for Basic Research (03-04-48000), from the Ministry of Education of Russia (St Petersburg Competition Center for Fundamental Sciences, E02-6-0-136; Program ‘Universities of Russia’, yp. 11-01-026). We sincerely thank Professor Ralf Paus (Department of Dermatology, Hamburg University) and Dr Vladimir Botchkarev (Department of Dermatology, Boston University Medical School) for reagents.

References


Houston KD, Copland JA, Broadus RR, Grottardis MM, Fischer SM & Walker CL 2003 Inhibition of proliferation and estrogen receptor...

Ing NH & Ott TL 1999 Estradiol up-regulates estrogen receptor-alpha messenger ribonucleic acid in sheep endometrium by increasing its stability. *Biofertility of Reproduction* **60** 134–139.


Received 3 May 2004
Accepted 24 May 2004
Made available online as an Accepted Preprint 1 June 2004

www.endocrinology.org